Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

JOHNSON & JOHNSON

(JNJ)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Johnson & Johnson : Janssen Says FDA Approves Darzalex Combination Regimen in Multiple Myeloma

share with twitter share with LinkedIn share with facebook
share via e-mail
0
06/27/2019 | 03:04pm EDT

By Michael Dabaie

Johnson & Johnson's (JNJ) Janssen Pharmaceutical Cos. said Thursday that the U.S. Food and Drug Administration approved Darzalex in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.

The approval is based on results from a Phase 3 clinical study, which showed the combination regimen reduced the risk of disease progression or death by 44% in newly diagnosed patients who are transplant ineligible, Janssen said.

This is the sixth Darzalex FDA-approved use in multiple myeloma and the second for newly diagnosed patients, the company said.

Write to Michael Dabaie at michael.dabaie@wsj.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on JOHNSON & JOHNSON
08/16JOHNSON & JOHNSON INVESTIGATION UPDA : Kahn Swick & Foti, LLC Continues to Inves..
BU
08/16JOHNSON & JOHNSON : Ebola Crisis-The Vaccines Debate
AQ
08/15JOHNSON & JOHNSON : Janssen Announces European Commission Approval of Imbruvica ..
AQ
08/13JOHNSON & JOHNSON : J&J's Janssen Gets EC OK for Expanded Use of Imbruvica
DJ
08/12JOHNSON & JOHNSON : Thinking about trading options or stock in AbbVie, Bristol-M..
PR
08/12JOHNSON & JOHNSON : Janssen Announces U.S. FDA Accelerated Approval for SIRTURO ..
AQ
08/09JOHNSON & JOHNSON : Janssen Announces U.S. FDA Accelerated Approval for SIRTUROÒ..
PU
08/09Canada enacts drug price crackdown, in blow to pharmaceutical industry
RE
08/09WHAT IS THE KEY OUTCOMES ANALYSIS OF : Pfizer, Amgen, Novartis, Bayer, Johnson &..
AQ
08/08JOHNSON & JOHNSON : to Participate in Barclays Global Consumer Staples Conferenc..
PR
More news
Financials (USD)
Sales 2019 81 594 M
EBIT 2019 25 389 M
Net income 2019 18 319 M
Debt 2019 6 116 M
Yield 2019 2,86%
P/E ratio 2019 19,6x
P/E ratio 2020 17,3x
EV / Sales2019 4,32x
EV / Sales2020 4,06x
Capitalization 347 B
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 149,05  $
Last Close Price 131,36  $
Spread / Highest target 28,7%
Spread / Average Target 13,5%
Spread / Lowest Target -5,60%
EPS Revisions
Managers
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Charles O. Prince Independent Director
William David Perez Independent Director
Anne M. Mulcahy Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON1.15%344 517
ROCHE HOLDING LTD.12.24%235 575
ROCHE HOLDING13.20%235 575
MERCK AND COMPANY11.32%213 689
NOVARTIS17.81%202 958
PFIZER-21.01%190 711